Immunotherapy drug improves outcomes for some children with relapsed leukemia

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.

Read more: https://www.eurekalert.org/pub_releases/2019-12/nci-idi120919.php